Novavax, Inc.: Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains

Trial is the first of its kind to evaluate a combined COVID-19 and influenza vaccineDose insights from Phase 1/2 trial will inform Phase 2 confirmation trial to begin in late 2022GAITHERSBURG

Related Keywords

Australia ,India ,Giovanna Chandler ,Erika Schultz ,Gregorym Glenn ,Vivek Shinde ,Linkedin ,European Commission ,Drug Administration ,Prnewswire Novavax Inc ,Nasdaq ,World Vaccine Congress ,Exchange Commission ,Serum Institute Of India ,Clinical Development ,Novavax Inc ,Influenza Combination ,Vice President ,Clinical Development Lead ,Older Adult ,Influenza Combination Vaccine Candidate Phase ,Serum Institute ,Financial Condition ,Novavax Annual Report ,Quarterly Reports ,Novavax ,Covid ,Influenza ,Combination ,Vaccine ,Candidate ,Induced ,Ntibody ,Fell ,Responses ,Against ,Cars ,Homologous ,Heterologous ,Trains ,